Our latest, in Science Advances: In vivo CRISPR screen revealed sgRNAs that switch chemosensitive SCLC PDXs to become resistant.We validated KEAP1 as key hit and found KEAP1 alterations in IMpower133 trial, where active NRF2 links to reduced survival in chemo arm www.science.org/doi/10.1126/... 1/2

Hello Bluesky! I’m a Professor at Fred Hutch and our lab studies the biology of small cell lung cancer. Using mouse and PDX models, cell-based and in vivo genetic screens, and genomic approaches, we seek to understand biologically distinct subsets of SCLC and their therapeutic vulnerabilities.